A. Karim Kader, MD, PhD, presented “Clinical Implications of Genetics in Prostate Cancer” during the 30th Annual International Prostate Cancer Update on January 23rd, 2020 in Beaver Creek, Colorado.
How to cite: Kader, A. Karim. “Clinical Implications of Genetics in Prostate Cancer” January 23rd, 2020. Accessed Nov 2024. https://dev.grandroundsinurology.com/clinical-implications-of-genetics-in-prostate-cancer/
Clinical Implications of Genetics in Prostate Cancer – Summary:
A. Karim Kader, MD, PhD, Professor in the Department of Urology and Director of Urologic Oncology at the University of California, San Diego, discusses the use of genetic and genomic prostate cancer markers as a risk assessment tool in men from screening to post-treatment workup. He describes several case studies in-depth, notes what markers were used for each individual case, and details the patient-specific outcomes associated with each case.
About The 30th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. Dr. Kader gave this presentation during the 30th iteration of the meeting in January 2020.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
A. Karim Kader, MD, PhD, is a board-certified urologist who specializes in screening, detecting, treating and preventing prostate cancer. As a Professor in the Department of Urology and Director of Urologic Oncology at the University of California, San Diego, Dr. Kader instructs medical students, residents and fellows at UC San Diego School of Medicine. His current research interests include genetic markers to assess risk and predict outcomes in urologic cancer. In addition, he examines the impact of augmented reality and enhanced imaging techniques for education and improved surgical outcomes. Dr. Kader completed a Fellowship in Urologic Oncology at the University of Texas MD Anderson Cancer Center in Houston and a Residency in Urology at the University of Toronto in Ontario, Canada. He earned his medical degree and doctoral degree from the University of British Columbia in Vancouver, British Columbia. Dr. Kader is nationally recognized for his expertise in performing robot-assisted radical cystectomy and urinary diversion for patients with bladder cancer. He holds several patents for genetic discoveries focused on the early detection and prevention of prostate cancer in addition to device patents for prostate cancer treatment. He is the principal investigator in numerous clinical research projects and has published extensively.
